NutriDex

The Supplement Research Compendium
🧠

Vinpocetine

Periwinkle-derived brain blood-flow agent; weak evidence, real pregnancy risk.

Mixed evidence 🧠Nootropic

✚ Updated · How we grade evidence

Evidence tier
Mixed
Research weight
Citations
7 verified / 7
Classification
Nootropic
❝
What the evidence says. Graded mixed: a 2003 Cochrane review found the dementia evidence inconclusive and not supportive of use, and although a 2022 meta-analysis of 4 small IV-stroke RCTs showed modest disability benefit, the trials are few, small and lower-quality. The FDA has concluded it is not a lawful dietary ingredient and warns it can cause miscarriage and fetal harm. (Mixed evidence: Conflicting results across studies; benefit uncertain.)

What is Vinpocetine?

Vinpocetine is a nootropic used for marketed for memory & focus. NutriDex grades the human evidence as Mixed. Vinpocetine is a synthetic molecule derived from vincamine, an alkaloid of lesser periwinkle (Vinca minor). It is a PDE1 inhibitor that widens cerebral vessels and is sold as a memory and focus nootropic. The strongest review, a 2003 Cochrane analysis of three dementia RCTs, judged the cognitive evidence inconclusive and insufficient to support clinical use. A 2022 meta-analysis of four small placebo-controlled trials of intravenous vinpocetine in acute ischemic stroke found modestly less disability at 1 month (SMD 0.49) and a small MMSE gain (WMD 0.92), but no mortality benefit and few, low-quality trials. Most positive data come from short, small studies of the prescription/IV form used abroad, not the oral supplement. In the US the FDA has stated vinpocetine is not a lawful dietary ingredient and warns it can cause miscarriage or fetal harm. Overall benefit for everyday cognition is unproven.

Purported Benefits

✓Marketed for memory & focus
✓Cerebral blood flow
✓Stroke recovery (clinical, IV)
✓Cognitive support in vascular disease

Evidence by outcome

The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.

OutcomeEvidenceEffectStudies
Improve memory/cognition in dementia or healthy users2003 Cochrane review judged dementia evidence inconclusive; an Alzheimer's RCT showed no efficacy. Mixed — no effect · negligible 2
Reduce disability after acute ischemic stroke (IV)Meta-analysis of 4 small RCTs found less 1-mo disability (SMD 0.49) with IV form, but no mortality benefit; low quality. Preliminary ↑ benefit · small 1
Improve acute-stroke functional outcomes (general)Earlier reviews found wide confidence intervals and no support for routine use; trials small/heterogeneous. Mixed ↔ mixed 2

Dosing & Compounds

Typical Dose
Oral studies used 5–10 mg three times daily (15–30 mg/day) of the synthetic compound; IV stroke trials used higher hospital-administered doses.
Active Compounds
Vinpocetine (ethyl apovincaminate)

Safety & Cautions

The US FDA has concluded vinpocetine is not a lawful dietary ingredient and warns that it may cause miscarriage or harm fetal development (based on NTP animal data showing reduced fetal weight at human-relevant blood levels) — pregnant women and those who could become pregnant should avoid it entirely. Because it widens vessels and may inhibit platelet aggregation, it can theoretically add to the effect of anticoagulants and antiplatelets (warfarin, aspirin, clopidogrel) and lower blood pressure. Reported side effects include headache, flushing, nausea, sleep disturbance and dizziness; it is not approved as a drug in the US and product quality is unregulated. Educational only — always check with your doctor or pharmacist before combining Vinpocetine with any medicine.

Key Studies

Meta-analysis Bhatti 2022 ✓ PubMed
Meta-analysis of 4 RCTs (837 pts): IV vinpocetine reduced disability at 1 mo (SMD 0.49) and 3 mo, MMSE +0.92; no mortality benefit (RR 0.94).
Systematic review Liu 2019 (protocol) ✓ PubMed
PROSPERO-registered protocol (CRD42018115224) to meta-analyse vinpocetine for post-stroke cognitive dysfunction; reflects unsettled evidence base.
Systematic review Szatmari & Whitehouse 2003 (Cochrane) ✓ PubMed
Review of 3 RCTs: evidence for benefit in cognitive impairment/dementia is inconclusive and does not support clinical use; few adverse effects.
Systematic review Bereczki & Fekete 1999 ✓ PubMed
Earlier systematic review of stroke trials: wide confidence intervals; no evidence to support routine use in acute ischemic stroke.
RCT Hindmarch 1991 ✓ PubMed
Pilot trial in acute ischaemic stroke; small single-blind study, inconclusive on functional outcomes.
RCT Thal 1989 ✓ PubMed
RCT in Alzheimer's disease: vinpocetine was safe but showed no efficacy on cognitive measures.
Review Al-Kuraishy 2020 ✓ PubMed
Critical review: signals for stroke recovery, post-stroke cognition and seizure reduction, but underpinned by small/heterogeneous trials.
7 sources cited · 7 verified Search all studies on PubMed ↗

Common questions about Vinpocetine

What is Vinpocetine used for?

Vinpocetine is most often taken for Marketed for memory & focus, Cerebral blood flow, Stroke recovery (clinical, IV), Cognitive support in vascular disease. Periwinkle-derived brain blood-flow agent; weak evidence, real pregnancy risk.

Does Vinpocetine work — what does the evidence say?

Mixed evidence. Conflicting results across studies; benefit uncertain. Vinpocetine is a synthetic molecule derived from vincamine, an alkaloid of lesser periwinkle (Vinca minor). It is a PDE1 inhibitor that widens cerebral vessels and is sold as a memory and focus nootropic. The strongest review, a 2003 Cochrane analysis of three dementia RCTs, judged the cognitive evidence inconclusive and insufficient to support clinical use. A 2022 meta-analysis of four small placebo-controlled trials of intravenous vinpocetine in acute ischemic stroke found modestly less disability at 1 month (SMD 0.49) and a small MMSE gain (WMD 0.92), but no mortality benefit and few, low-quality trials. Most positive data come from short, small studies of the prescription/IV form used abroad, not the oral supplement. In the US the FDA has stated vinpocetine is not a lawful dietary ingredient and warns it can cause miscarriage or fetal harm. Overall benefit for everyday cognition is unproven.

What is the typical dose of Vinpocetine?

Oral studies used 5–10 mg three times daily (15–30 mg/day) of the synthetic compound; IV stroke trials used higher hospital-administered doses.

Is Vinpocetine safe? Any cautions or side effects?

The US FDA has concluded vinpocetine is not a lawful dietary ingredient and warns that it may cause miscarriage or harm fetal development (based on NTP animal data showing reduced fetal weight at human-relevant blood levels) — pregnant women and those who could become pregnant should avoid it entirely. Because it widens vessels and may inhibit platelet aggregation, it can theoretically add to the effect of anticoagulants and antiplatelets (warfarin, aspirin, clopidogrel) and lower blood pressure. Reported side effects include headache, flushing, nausea, sleep disturbance and dizziness; it is not approved as a drug in the US and product quality is unregulated.

How many studies support Vinpocetine?

NutriDex cites 7 sources for Vinpocetine, graded "Mixed".

Cite this page
APA

Peh, D. (2026). Vinpocetine: Benefits, Dosage, Side Effects & Evidence. NutriDex — The Supplement Research Compendium. Retrieved 26 Jun 2026, from https://nutridex.info/s/vinpocetine

BibTeX
@misc{nutridex_vinpocetine,
  author       = {Peh, Daryl},
  title        = {Vinpocetine: Benefits, Dosage, Side Effects \& Evidence},
  year         = {2026},
  howpublished = {NutriDex --- The Supplement Research Compendium},
  url          = {https://nutridex.info/s/vinpocetine},
  note         = {Reviewed by Dr Daryl Peh, MBBS Singapore, MMed FM. Accessed 2026-06-26}
}

For medical claims, citing the underlying primary studies linked above is preferred. NutriDex is an educational reference, not medical advice.

← Back to the full dex · All substances